Koho ʻo Peptide CRO no ka pae 1 Ma lalo o ka hana TrialBlazer

Pane wikiwiki

How to score peptide CROs for Phase 1 under Operation TrialBlazer: ʻike ʻike, ka maemae, stability and release evidence that survives a rolling IND review.

He aha ka hana TrialBlazer e hoʻololi maoli ai no ke koho ʻana i ka Peptide CRO no ka pae 1

he kahe maʻalahi e hōʻike ana i nā ʻāpana IND e neʻe ana i ka FDA ma ke ʻano o ka wā ma mua o ka IND, me kahi keʻena noiʻi kūpono ma kahi ʻōlelo aʻoaʻo r

Ua hoʻololi ʻia ka hoʻomohala ʻana o ka peptide Operation TrialBlazer i Kepakemapa 15, 2026, i ka wehe ʻana o ka FDA i nā noi no ka Expedited IND Pilot, ka papahana i hoʻokele ʻia e ke keʻena i loko o ka hoʻolālā TrialBlazer ākea a HHS (ka hoʻolaha hoʻolaha ʻo IND Pilot ʻo FDA, 2026-09-15). Wehe ka papahana no nā noi a hiki i 11:59pm ET ma ʻOkakopa 30, 2026, a ke manaʻo nei ʻo FDA e koho i 8-10 mau hoa kākoʻo-QRI no ka hui mua (ka palena manawa noi, ʻike i kēia manawa 2026-09-21).

Koho ʻo Peptide CRO no ka pae 1 Ma lalo o ka hana TrialBlazer

Ke kaʻina hana, aole oluolu. Hāʻawi nā hui noiʻi kūpono i ka ʻike ʻepekema kūikawā i ka hoʻomākaukau IND, ka mea e ʻae ai i ka FDA e loiloi a ʻae i nā ʻāpana pākahi i ka wā o ka wā pre-IND ma mua o ke kali ʻana i ka pūʻolo piha. (pehea e holo ai ka loiloi pre-IND, 2026-09-15). ʻO ka manaʻo o FDA e hopu a hoʻoponopono i nā pilikia i ka manawa maoli, e hoemi ana i ka pilikia o ka paa mua o ke kanaka (ka manaʻo i ʻōlelo ʻia e ka mea hoʻokele, 2026-09-15). Mālama ʻo FDA i ka mana hoʻoponopono piha a puni, me ka hoʻoholo e hoʻokau i kahi paʻa lapaʻau (Mālama ʻo FDA i ka mana hoʻoponopono piha, 2026-09-15).

Ki Takeaway: Hoʻololi ke pilot ke nānā ʻia nā ʻāpana, ʻaʻole ka mea i manaʻo ʻia iā lākou. Ua wehe ʻo FDA i kekahi mau Phase 1 Nā kuleana CMC (he aha ka FDA i manaʻo maoli ai i kahi Phase 1 ʻāpana CMC, ʻike i kēia manawa 2026-06-22), no laila, ʻo ka pae e piʻi maoli ana ma luna o ka hiki i ka hoa hana a me ka pale ʻana i nā ʻano hana kūpono i loko o kahi kamaʻilio ʻōwili ola. (ka pahu e piʻi maoli ana, 2026-06-18 i 2026-09-21).

ʻO kēlā ʻokoʻa ke kumu holoʻokoʻa o ka koho peptide CRO no ka Phase 1 malalo o keia papahana.

ʻAʻole hoʻomaha ka wikiwiki o nā kumu kumu ʻehā

Hoʻololi ʻo Operation TrialBlazer i ke kaʻina loiloi, ʻaʻole ke kūlana hōʻoia. ʻO ka ʻōlelo aʻo CMC kūpono o ka FDA e paʻa ana e "pono ​​​​e waiho ʻia ka ʻike e hōʻoia i ka ʻike kūpono., maikaʻi, ka maemae, a me ka ikaika o ka laau hookolokolo,” me ka nui e hoʻololi ʻia e ka pae, hoʻomāmā, a me ka lōʻihi o ke aʻo ʻana (FDA CMC no nā IND, kiʻi ʻia 2026-06-22). ʻO ia ke kumu e neʻe ʻole ai nā kumu: ʻO nā ʻano hōʻoia ʻehā nā inoa FDA he ʻike, maikaʻi, ka maemae, a me ka ikaika, a me ka ʻāpana CMC e uhi ana i ka mea lāʻau, huahana lāʻau, placebo, a pili mau ka lepili ma Phase 1. ʻO ka mea i ʻae ʻia e ka "nui pono" he liʻiliʻi ka ʻikepili, ʻaʻole hōʻike nāwaliwali. E nānā i ka palena o ka moʻolelo: Ua kākau ʻia ka wehewehe ʻike liʻiliʻi o ka FDA no nā molekele liʻiliʻi a me nā huahana ola hou, a ʻaʻohe peptide-specific Phase 1 Loaʻa ka ʻaoʻao ʻaoʻao CMC ma ka pūnaewele FDA, no laila pono nā mea kākoʻo peptide e heluhelu i ke aʻo ʻana ma ke ʻano he kumu a hōʻoia i nā kikoʻī me CDER.

Kumukūʻai

ʻO nā mea hōʻike e hōʻike ana

Kapa inoa maʻamau

ʻIkepili

Hōʻoiaʻiʻo Orthogonal, no ka laʻana, ka nui o ka spectrometry me ka nānā ʻana i ka waikawa amino

I Q2(R2)

ʻAno maikaʻi

ʻO nā moʻolelo pūʻulu a me ka hoʻokuʻu ʻana i ka hoʻāʻo hiki ke ʻike ʻia i ka ʻikepili kumu

Nā loina MHRA ALCOA

Maemae

ʻO ka ʻokiʻoki ʻana i ka ʻaoʻao haumia, epimers, a me nā huahana degradation

I Q2(R2)

Ka ikaika

ʻO ka hoʻāʻo ʻana o ka maʻiʻo peptide me ke kumu counter-ion i wehewehe ʻia

USP monographs inā pili

Papakaukau: Māhele 1 peptide CMC koi i palapala ʻia i ka artifact e hōʻike ana i kēlā me kēia.

No ke kōkua: Paʻa ka laulā i ka Phase 1 ka lōʻihi o ke aʻo ʻana a me nā kūlana mālama maoli ma mua o kahi papahana lōʻihi paʻamau.

Pehea e loiloi ai i ka ʻike a me ka hiki ke maʻemaʻe o kahi Peptide CRO

he laʻana chromatogram i hōʻike ʻia me kahi kiʻekiʻe haumia ʻoki i hoʻoholo ʻia e pili ana i ka piko peptide nui., hōʻailona ʻia

ʻO nā koi ʻike a me ka maʻemaʻe wale nō ka ikaika e like me nā ʻano orthogonal ma hope o lākou. E nīnau inā hoʻopili ka pūʻolo i ka hoʻopaʻa ʻana o ka waikawa amino me ka HPLC a me ka spectrometry, inā paha e hoʻokaʻawale ka hoʻopili ʻana i ka haumia i nā mea haumia kaʻina mai ka ʻoki ʻana, epimers, a me nā huahana degradation, a inā hāʻawi ʻia nā chromatograms maka ma mua o ka hōʻuluʻulu ʻana. ʻO kēia nā ʻano hōʻoia e nānā ʻia e ka mea loiloi, a noho lākou ma waho o ka mea i manaʻo ʻole ʻia e FDA ma mua o ke kanaka ma lalo o ka Phase 1 papa inoa maʻalahi.

ʻOi aku ka haʻi ʻana o nā mea hana koneki iā ʻoe ma mua o nā ʻōlelo hiki. E noi i ka palapala hōʻoia no ka nānā ʻana, nā chromatograms piha, a me ke ʻano o ka hōʻuluʻulu manaʻo, a heluhelu iā lākou e pili ana i ke ʻano o ka ʻano kikoʻī e like me ka mea loiloi i nā ʻike hemahema o ka comparative-peptide-impurity deficiency FDA..

ʻO kahi CRO e hāʻawi ana i nā mea waiwai ʻekolu me ka nīnau ʻole ʻia e hōʻike ana i ka hiki ke hoʻāʻo i ka hoʻomaʻemaʻe hoʻomaʻemaʻe peptide ma ke ala wale nō e helu ai.: palapala ʻia, kākoʻo ʻia, a hiki ke nana.

Pehea e loiloi ai i nā ʻano hana e hōʻike ana i ke kūpaʻa a me ka hōʻoia kūpono

Māhele 1 ʻO ka maʻalahi o ka hōʻoia ʻana i ke ʻano analytical no nā peptides he alana staging, ʻaʻole he waiver, a hāiki i ka holomua ʻana o ka papahana. Ka Phase 1 CMC flexibilities FDA lists that analytical method validation data, ʻikepili kūpaʻa hoʻopaʻa kino-nui, ka uhi paʻa piha, a me nā kaʻina hana pili ʻole i ka palekana ʻaʻole i manaʻo ʻia ma mua o ke kanaka. Hoʻopaneʻe ʻia kēlā mau mea, ʻaʻole i holoi ʻia: No ke aha i hōʻemi ai ka maʻalahi i ka holomua ʻana o ka papahana ʻo ka nui o ka ʻike CMC e pono ai ke hahai i ka pae, no laila ka pūʻolo hoʻokahi e hoʻopiha i kahi Phase 1 ʻAʻole e lawe ʻo IND i kahi Phase 2 waiho ana. ʻO ka manaʻo o FDA no ka hoʻemi ʻana i ka manawa hoʻomohala noi e kau i ka Phase 1 pōmaikaʻi a hiki i 12 mahina, ʻo ia ka puka makani hiki ke hoʻopau ʻia kahi ʻano ʻano lahilahi i ka hana hou.

⚠️ ʻŌlelo Aʻo: ʻO kahi puʻupuʻu ʻano lahilahi e pane i kahi nīnau FDA e hoʻoikaika wikiwiki i ka hana hou ma lalo o kahi uaki paʻa, a ua pau ka haawina mahina 12.

ʻO ka mea a ka mea kākoʻo e pale aku ai, ʻo ia ke ʻano kūpaʻa o ke ʻano ponoʻī: e hoʻokaʻawale a helu i nā mea hoʻohaʻahaʻa i hana maoli ʻia e ka peptide.

Pehea e loiloi ai i ka Endotoxin, ʻO ka maʻemaʻe, a hoʻokuʻu i nā kikoʻī no nā peptides

Hoʻohuihui Peptide ʻO nā kikoʻī hoʻokuʻu kahi i ʻike ʻia ai nā palena maoli o kahi hoa, maʻa mau ma hope o kāu hana ʻana. No ka peptide makua, helu ʻia ka palena endotoxin bacteria e like me K/M, ma kahi o K ka paepae pyrogenic no ka kilo i ka hola (5 EU/kg no ka hapanui o nā ala makua) a ʻo M ka nui o ke kino kanaka no ka kilo i ka hola. A 70 kg ma'i e loaa ana a 1 Hāʻawi ka mg / kg i ka M = 1 mg/kg/hr, pela ka palena 5 EU/kg ÷ 1 mg/kg = 5 EU/mg. Hoʻololi ke ala i ka helu helu: Hoʻohana nā huahana intrathecal i kahi K, no laila hiki i ka peptide like ke alo i nā kauoha palena o ka nui. ʻO nā manaʻolana hoʻomaʻemaʻe e hahai i ka loina like, no ka mea, pono ka injectable sterile i hoʻopaʻa ʻia i ka hana aseptic a i ʻole sterilization terminal me nā ʻikepili kākoʻo.

Ke nānā ʻoe i nā mea hoʻolako, hoʻokahi mea kūʻai i paʻi ʻia nā hae ʻulaʻula He mea pono ia ma ke ʻano he papa helu koho ʻia ma mua o kahi hōʻailona: ʻaʻohe peptide-specific reference a i ʻole nā ​​manaʻo hiki ʻole, hoʻāʻo analytical piha i waho, nā leka ʻōlelo aʻo hou a i ʻole e hana hou 483 nā nānā ʻana, a me ka hilinaʻi nui i ka mea kūʻai hoʻokahi no ka loaʻa kālā. E mālama i kēia mau nīnau e nīnau ai, ʻaʻole nā ​​paepae e kiʻi kūʻē.

Ke kūkulu ʻana i ka Matrix Hoʻoholo no ke koho ʻana i ka Peptide CRO no ka Phase 1

E helu i kēlā me kēia moho ma ka hiki ke hana hōʻike, ʻaʻole i ka wikiwiki o kāna koi ʻana e neʻe. ʻO kahi peptide CDMO scorecard i paʻi ʻia e hiki ke hoʻohui i ka mana kiʻekiʻe ma 25%, ukali e analytical a me QC ma 20%, mōʻaukala hoʻoponopono ma 20%, hiki a me scalability ma 15%, ʻōnaehana maikaʻi ma 10%, a me ke kālā a me ka hoʻolālā kūpono i 10% (Koho Koho CDMO Peptide, loiloi ʻia ʻApelila 2026). E mālama i kēlā ma ke ʻano he ʻano hoʻohālike wale nō: ʻAʻole hoʻopuka ke kumu i ke ʻano hana ma hope o nā kaupaona, a ʻaʻole ia he mea hōʻike e kākoʻo ana i nā pae paona ma kēia ʻano. E hoʻonoho i kāu mau kaupaona ponoʻī, a laila hoʻohui i ka lālani i ʻoi aku ma mua o nā mea ʻē aʻe.

Kūlana

Kaumaha

Moho A

Moho B

Moho C

pae hōʻoia QRI

Kiekie loa

ʻO nā Peptides Synthetic

Nā lawelawe

Hiki ke hoʻohui

Analytical a me QC

hale kūʻai

Moolelo hooponopono

Ka nui a me ka scalability

Pūnaehana maikaʻi

Kūpono kālā a me ka hoʻolālā

Lawe ka laina QRI i ke kaumaha kiʻekiʻe loa no ka mea ua noʻonoʻo ʻia nā CRO ma ke ʻano he mau keʻena noiʻi kūpono.: Ua haʻi aku ka luna CDER ʻo Michael Davis i nā mea hoʻolaha i nā QRI "hiki ke lilo i mau kikowaena olakino a i ʻole nā ​​​​hui noiʻi ʻaelike" (BioSpace, Kepakemapa 15, 2026). E helu i kēlā lālani he aha ka manaʻo QRI e koi ai: hōʻike ʻia nā mana, ʻoihana, a me ka ʻike alakaʻi ma ka nonclinical, lāʻau lapaʻau, a me nā hoʻopaʻi CMC, nā mea hoʻoponopono, a me nā hoʻokolohua lapaʻau pili i nā IND a me ka Phase mua-i-kanaka 1 nā haʻawina. E nānā i ka palena. Hana nā QRI ma ke ʻano he loiloi a me nā kumu aʻoaʻo, a ke kuleana nei ka poʻe kākoʻo i kā lākou mau hoʻouna IND.

ʻO nā hewa maʻamau i hana ʻia e nā mea kākoʻo ma lalo o kahi laina manawa wikiwiki

ʻO ka hāʻule hou ʻana ma lalo o kahi manawa wikiwiki e heluhelu ana i ka "phase-appropriate" ma ke ʻano he "koho." He ʻoiaʻiʻo nā ʻano maʻalahi akā haiki, a ʻo ka poʻe kākoʻo nāna e mālama iā lākou ma ke ʻano he waiver maʻamau e lawe i ke kumukūʻai ma hope e like me ka hana hou ʻana ma lalo o kahi uaki paʻa.

Hoʻopaneʻe i ka hoʻopili ʻana i ka haumia. ʻO nā hui ma lalo o ke kaomi milestone e holo i ka ʻike a me ka hoʻomaʻemaʻe e hoʻokuʻu mua a hoʻopanee i ka hoʻomohala ʻana i ke ʻano haumia. ʻO ka hoʻoponopono ʻana, ʻo ka hoʻopaʻa ʻana i nā mea haumia i ka wā mua i mākaukau ke ʻano ma mua o ka hoʻomaka ʻana o ka pūʻulu, no ka mea, ʻaʻole hiki ke pane hou ʻia ka nīnau loiloi e pili ana i kahi piko i ʻike ʻole ʻia.

Ke kūkulu nui ʻana i ka papahana kūpaʻa. ʻO ka hewa kū'ē: ka hoʻolālā ʻana i kahi pūʻolo kūpaʻa pāʻoihana no kahi Phase 1 moho. E hoʻohālikelike i ka papahana me ka pae a me ka lōʻihi i manaʻo ʻia.

Hoʻouna ʻana i kahi pūʻolo ʻano lahilahi. ʻO kahi pūʻolo hiki ʻole ke pane i ka nīnau a ka mea loiloi e hoʻopaʻa i ka waiho ʻana. E mālama i ka hōʻoia ʻana i ke ʻano analytical no nā peptides e like me ka mea hiki ke hāʻawi, ʻaʻole nā ​​pepa a puni.

Ka mālama ʻana i ka QRI ma ke ʻano he hoʻoili kuleana. Noho ka poʻe kākoʻo i ke kuleana no kā lākou hoʻouna ʻana; ʻO kahi keʻena noiʻi kūpono e hana ma ke ʻano he loiloi a me nā kumu aʻoaʻo.

He aha ka holomua ma ka hopena o ke koho ʻana i ka Peptide CRO

Loaʻa i ka koho peptide CRO no ka Phase 1 he hoa pili nona nā palapala e pane i ka nīnau a ka mea loiloi me ka ʻole o ka pōʻai lua. Pono ʻoe e noi i ka papa inoa kiʻi piha, loaa ma ka pane hookahi, a hāʻawi iā ia i kahi loiloi hoʻoponopono me ka ʻole o ka hahai ʻana i nā ʻāpana nalowale.

Hoʻopaʻa palapala ʻia nā hōʻailona hōʻoia i ka pae hiki ke hoʻomaʻemaʻe ʻia e kahi hoa kūpono: nā ala kūpono i ka pae āu i komo ai, ʻoi aku ka paʻa i ke aʻo ʻana ma mua o ka hoʻopiʻi mālama ola maʻamau, a me kahi hui hoʻoponopono i kapa ʻia nāna e pane pololei i nā nīnau ʻenehana ma mua o ke alakaʻi ʻana iā lākou ma kahi ala kūʻai. He mea nui loa kēlā hōʻailona hope inā ʻo kāu IP ka waiwai i pilikia, no ka mea, hoʻopōkole ka mea hoʻopili i kapa ʻia i ka puka kamaʻilio a hoʻemi i ka nui o nā poʻe e pā i kāu kaʻina. Hana ʻia ʻo Peptide

Hōʻike ka MOL Changes i ke ʻano o kahi pūʻolo peptide paʻa palapala: a CoA, HPLC chromatogram, a me MS spectrum me kēlā me kēia kauoha, HPLC analytical no ka maemae, ESI-MS a i ʻole MALDI-TOF no ka ʻike, a me ka nānā ʻana i ka waikawa amino no ka ʻike, hanaia ma ka Papa 100 lumi hoʻomaʻemaʻe maʻemaʻe kiʻekiʻe kiʻekiʻe ma ka paona milligram-a-kilogram. E hoʻomaopopo he hiki ke kālailai kēia, ʻaʻole kākoʻo hoʻoponopono; ʻaʻole hōʻoia ka waihona ʻike i nā lawelawe IND-file, no laila e mālama i kēlā ma ke ʻano he loiloi loiloi kaʻawale.

Hōʻike kālepa: Loaʻa i ka MOL Changes kahi hoihoi pāʻoihana i nā kūlana maikaʻi peptide.

Mākaukau e loiloi i kahi palapala peptide piha piha? E noi i kahi kūkākūkā kikoʻī peptide a lawe mai i kāu papa inoa kiʻi kiʻi i ke kamaʻilio.

Nīnau pinepine

Hiki iaʻu ke noi i ka Expedited IND Pilot ma hope o ʻOkakopa 30, 2026?

ʻAʻole. Hoʻopau ka puka hoʻohana i ʻOkakopa 30, 2026 ma 11:59pm ET, a ʻaʻole i hoʻopuka ʻo FDA i kahi cohort ʻelua a i ʻole hoʻonui. Inā ʻoe e kaupaona nei i ka hoʻomohala ʻana i ka peptide Operation TrialBlazer no kahi Phase 1 papahana, ʻO ka nīnau kūpono ʻaʻole inā e noi akā inā hiki ke hōʻuluʻulu ʻia kāu pūʻolo CMC ma mua o kēlā lā. Pono nā mea kākoʻo i hiki ʻole ke hālāwai me ia e hoʻolālā no ke ala IND maʻamau ma mua o ka manaʻo e wehe ʻia kahi puka makani hahai..

Ke hana nei me kahi ʻoihana noiʻi kūpono e hoʻololi i ke kuleana IND?

ʻAʻole. Manaʻo nā QRI; hāʻawi nā mea kākoʻo. Hana ʻia kahi ʻoihana noiʻi kūpono ma ke ʻano he loiloi a me ka ʻōlelo aʻoaʻo, a na ka mea kākoʻo ke kuleana no ka ʻike, pololei, a me ka piha o na mea a pau i waihoia. E mālama i nā manaʻo manaʻo QRI ma ke ʻano he manaʻo loea i kāu loiloi ponoʻī, aole i pani, a mālama i kāu moʻolelo no ka hoʻoholo ʻana i kēlā me kēia manaʻo. E pili ana

Hana i ka Phase 1 hiki ke hoʻololi i ka hōʻoia ʻana i ke ʻano analytical i ka Phase 2?

ʻAʻole ma ke ʻano like. Ua kūpono ka maʻalahi ma ka hoʻolālā ʻana a hāiki i ka holomua ʻana o ka papahana, ʻo ia ke kumu o ka Phase 1 ʻAʻole hiki ke hoʻololi i mua me ka loli ʻole. Pono e hoʻolālā ʻia ka hōʻoia ʻana i ke ʻano analytical no nā peptides ma ke ʻano he hana hoʻokō, me ka ʻikepili hōʻoia piha i manaʻo ʻia ke hoʻokokoke ʻoe i nā pae hope. E hōʻoia i nā manaʻolana o kēia manawa me FDA ma mua o kou laka ʻana i kāu Phase 2 hoʻolālā.

Pehea e loli ai ka palena endotoxin no kahi peptide intrathecal?

Pili ka palena i ke ala, helu ʻia ʻo K i puʻunaue ʻia e M, ʻo K ka paepae pyrogenic dose a ʻo M ka palena kiʻekiʻe o ke kanaka no ka kilo i kēlā me kēia hola. No ka mea, ʻoi aku ka liʻiliʻi o ka dose intrathecal ma mua o ka intravenous, ʻoi aku ka paʻa o ka palena endotoxin i ʻae ʻia. E hoʻonohonoho i ka ʻōlelo kikoʻī mai kāu kau palena kiʻekiʻe a me ke ala, a hōʻoia i ka helu ʻana me kāu hui analytical ma mua o ka hoʻokuʻu ʻana i ka hoʻāʻo.

Ka hopena

Koho ʻo Peptide CRO no ka Phase 1 ma lalo o Operation TrialBlazer e iho mai i kahi reframe: hoʻopōkole ka pailaka i ka manawa, ʻaʻole ka hōʻike e noi ai ka mea loiloi. He hoa hana hiki ke hana i ka ike, ka maemae, kūpaʻa, a ʻoi aku ka maikaʻi o ka hoʻokuʻu ʻana i ka ʻikepili e kū nei ma mua o ka mea nāna i hoʻohiki i ka kalena wikiwiki loa, no ka mea, ʻo ka lua o nā nīnau kahi e nalowale ai nā polokalamu wikiwiki i ko lākou pono. E helu i kēlā me kēia moho ma ka nīnau hoʻokahi: i ka wā e hoʻopiʻi ai ka mea loiloi i kahi moʻolelo haumia, he ʻano hōʻike kūpaʻa, a i ʻole ka palena endotoxin, Hiki i kēia hoa ke pane me nā palapala i ka lima? E hoʻohana i ka matrix hoʻoholo mai kēia alakaʻi e kaupaona i kēlā mana me ke kumukūʻai a me ka manawa, a hoʻomaka i ke kamaʻilio me kāu papa inoa ma mua o ʻOkakopa 30, 2026 pani pukaaniani.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana